Neurocrine Biosciences (NBIX) revenue

Revenue · fiscal 2025
$2.86B

Neurocrine Biosciences (NBIX) reported revenue of $2.86B in fiscal 2025 (the year ended December 31, 2025). That is 21.4% higher than the $2.36B of fiscal 2024. Figures as of 18 Nov 2026, 12:07 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$2.86B
Change on fiscal 2024
+21.4%
Growth, 5 years
+22.3% a year
Growth, 10 years
+64.5% a year
Highest on record
$2.86Bfiscal 2025
Lowest on record
$2.92Mfiscal 2013
Fiscal years on record
162009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Neurocrine Biosciences revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 22.3% a year; over ten years the rate was 64.5% a year. Across the 16 fiscal years on record (2009–2025), the highest was $2.86B in fiscal 2025 and the lowest $2.92M in fiscal 2013.

History · 16 fiscal years

Revenue by fiscal year

Neurocrine Biosciences revenue, year by year

Neurocrine Biosciences (NBIX) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$2.86B 21.4% up
2024$2.36B 24.8% up
2023$1.89B 26.8% up
2022$1.49B 31.3% up
2021$1.13B 8.4% up
2020$1.05B 32.7% up
2019$788.10M 74.7% up
2018$451.20M 179.2% up
2017$161.63M 977.5% up
2016$15.00M 24.1% down
2015$19.77M—
2013$2.92M 94.5% down
2012$53.14M 31.4% down
2011$77.41M 131.1% up
2010$33.50M 1,034.5% up
2009$2.95M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Neurocrine Biosciences and comparable companies
CompanyRevenueFiscal year
Revvity RVTY$2.86B2025
Exelixis EXEL$2.32B2025
Charles River Laboratories International CRL$4.02B2025
Neurocrine Biosciences NBIX$2.86B2025
Ascendis Pharma ASND€720.13M2025
ICON ICLR$8.25B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on NBIX

Neurocrine Biosciences, figure by figure

Neurocrine Biosciences (NBIX) overview: price, valuation and scorecardAll health care companies by market value

Neurocrine Biosciences revenue: questions and answers

What is Neurocrine Biosciences's revenue?

Neurocrine Biosciences (NBIX) reported revenue of $2.86B in fiscal 2025 (the year ended December 31, 2025). That is 21.4% higher than the $2.36B of fiscal 2024.

What is the growth rate of Neurocrine Biosciences's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 22.3% a year; over ten years the rate was 64.5% a year.

What are the highest and lowest revenue figures on record for Neurocrine Biosciences?

Across the 16 fiscal years on record (2009–2025), the highest was $2.86B in fiscal 2025 and the lowest $2.92M in fiscal 2013.

How is Neurocrine Biosciences's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Neurocrine Biosciences it is on record here for 16 fiscal years, 2009 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Neurocrine Biosciences (NBIX) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/NBIX/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.